EXTENDED THERAPY OF VENOUS THROMBOSIS BY ORAL ANTICOAGULANTS: FOCUS AT SAFETY

Study objective: to evaluate safety of prolonged therapy of venous thrombosis by rivarixaban compared to the standard scheme of therapy by low-molecular heparins (LMH) with subsequent transfer to warfarin administration. Materials and methods. Prospective observation comparative study was conducted that included 243 patients with verified venous thrombosis. The control group included 96 patients to whom therapy by LMH/warfarin was prescribed. The major group included 147 patients to whom rivaroxaban was prescribed. Results. The frequency of major hemorrhages reached 0% in the major group versus 2% in the control group (р = 0.32). The total frequency of hemorrhagic complications development amounted to 10.2% in the major group and 12.5% in the control one (p = 0.73). 86.7% of patients of the major group and only 50% of the control group (р = 0.049) continued the anticoagulant therapy after development of hemorrhagic complications. Conclusions: the results obtained by us confirm higher safety of rovaroxaban use compared to warfarin within prolonged therapy of venous thrombosis. These data correspond to the results of the previously published studies EINSTEIN and XALIA.

1. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. The American journal of medicine, 2004. 117(1): 19-25.

2. Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboem bolism: prospective cohort study. BMJ, 2011, 343: d4656.

3. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. Journal of thrombosis and haemost asis: JTH, 2007, 5(4): 692-9.

4. Spencer FA, Emery C, Lessard D, Anderson F, Emani S. Aragam J, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology o f venous thromboembolism. Journal of general internal medicine, 2006, 21(7): 722-7.

5. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H. et al., Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expe rt Panel Report. Chest, 2016, 149(2): 315-52.

6. Van Es J, Eerenberg ES., Kamphuisen PW, Buller HR. How to prevent, treat, and overcome current clinical challenges of VTE. Journal of thrombosis and haemostasis: JTH, 2011, 9(Suppl 1): 265-74.

7. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clin ical Practice Guidelines. Chest, 2012, 141(2 Suppl): 7S-47S.

8. Бокерия Л.А., Зат евахин И.И., Кириенко А.И., Андрияшкин А.В., Андрияшкин В.В., Арутюнов Г.П. и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений, Флебология, выпуск 2, 2015, 9(4): 2-52. / Bokeria L.A., Zatevakhin I.I., Kirienko A.I., Andriyashkin A.V., Andriyashkin V.V., Arutyunov G.P. et al. Russian Clinical Recommendations on Diagnostics, Therapy, and Prevention of Venous Thromboem bolic Complications, Flebologia, issue 2, 2015, 9(4): 2-52.

9. Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist fo r the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEINDVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. The Lancet. Haematology, 2014, 1(1): e37-46.

10. Schulman S. Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of thrombosis and haemostasis : JTH, 2005, 3(4): 692-4.

11. Boutitie F, Pinede L, Schul man S, Agnelli G, Raskob G, Julian J et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ, 2011, 342: d3036.

12. Lader E, Martin N, Cohen G, Meyer M, Reiter P, Dimova A et al. Warfari n therapeutic monitoring: is 70% time in the therapeutic range the best we can do? Journal of clinical pharmacy and therapeutics, 2012, 37(4): 375-7.

13. Mearns ES, Kohn CG, Song JS, Hawthorne J, Meng J, White CM et al. Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients. Thrombosis research, 2014, 134(2): 310-9.

14. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous t hromboembolism: a meta-analysis. Annals of internal medicine, 2003, 139(11): 893-900.

15. Punthakee X, Doobay J, Anand SS. Oralanticoagulant- related intracerebral hemorrhage.

16. Thrombosis research, 2002., 108(1): 31-6.

17. Ca rrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Annals of internal medicine, 2010, 152(9): 578-89.

18. Pra ndoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R. et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica, 2007, 92(2): 199-205.

19. Roussin A. Effective m anagement of acute deep vein thrombosis: direct oral anticoagulants. International angiology: a journal of the International Union of Angiology, 2015, 34(1): 16-29.

20. Sardar P, Chatterjee S, Herzog E, Pekler G, Mushiyev S, Pastori LJ et al. New or al anticoagulants in patients with cancer: current state of evidence. American journal of therapeutics, 2015, 22(6): 460-8.

21. Skaistis J, Tagami T. Risk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-Analysis. PloS one, 2015, 10(9): e0 137444.

22. Caldeira, D, Barra M, Pinto FJ, Ferreira JJ, Costa J. Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. Journal of neurology, 2 015, 262(3): 516-22.

23. Eerenberg ES, Middeldorp S, Levi M, Lensing AW, Büller HR. Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. Journal of thrombosis and haemostas is : JTH, 2015, 13(9): 1590-6.

24. Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of sympt omatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. The Lancet. Haematology, 2016, 3(1): e12-21.